An OpenAI researcher is leaving to build a $2bn AI drug startup that has no name yet
THE SO WHAT
A pre-name, pre-product AI drug startup targeting a ~$2B valuation on ~$200M raised shows capital is still willing to underwrite talent and thesis alone in this niche. Pharma and biotech operators should expect deal competition for AI-native partners to stay frothy, even if broader venture cools.
READ THE SOURCE
MORE FROM THE WIRE
Startups & VentureWhy Greylock capped its new fund at $1.5B when it says it could have raised more
A $1.5B cap and ~25 checks per fund is a bet that partner time, not capital, is the scarce resource in early-stage. If you’re raising or allocating now, assume the best firms will trade check size for attention and expect you to do more with less money but more direct help.
Startups & VentureData Center Firm Csquare Is Said to Price IPO at $21 Per Share
Csquare pricing its IPO below the marketed range suggests public investors are getting choosier on data center growth stories despite AI demand. If you’re in infra, assume you’ll need clearer visibility on power, utilization, and customer mix to clear public or late-stage capital at target valuations.
Startups & VentureStripe’s Acquisition Pace Has Accelerated In The Past Five Years, But Nothing Comes Close To Its Reported $53B PayPal Bet
A reported $53B move on PayPal would be Stripe trying to consolidate consumer and merchant rails into a single operating layer for online payments. Fintech founders should assume the bar for independent scale just went up—niches, geography, or deeply vertical workflows become the safer ground.
Startups & VentureNeko Health raises $700M at nearly $7bn and heads to New York
A $700M raise at a ~$7B valuation for Neko Health is a strong bet that high-throughput body scanning becomes a consumer entry point to diagnostics. U.S. providers and payers should assume patients will show up with third-party scans and expectations for faster triage — integration and interpretation workflows need to exist before that wave hits.